218 related articles for article (PubMed ID: 25037257)
1. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.
Choi JN
Semin Cutan Med Surg; 2014 Mar; 33(1):40-8. PubMed ID: 25037257
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
3. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].
Gutzmer R; Hassel JC; Kähler KC; Loquai C; Mössner R; Ugurel S; Zimmer L; der das Ado FK
Hautarzt; 2014 Jul; 65(7):582-9. PubMed ID: 24903029
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
[TBL] [Abstract][Full Text] [Related]
5. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
8. Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor.
Fawaz B; Dickson L; Menter A
J Dermatolog Treat; 2016 Oct; 27(5):418-21. PubMed ID: 27080364
[TBL] [Abstract][Full Text] [Related]
9. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
10. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
[TBL] [Abstract][Full Text] [Related]
11. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
[TBL] [Abstract][Full Text] [Related]
13. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
[TBL] [Abstract][Full Text] [Related]
14. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous drug eruptions associated with the use of new oncological drugs.
Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
[TBL] [Abstract][Full Text] [Related]
16. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
17. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
19. Skin Manifestations of Targeted Antineoplastic Therapy.
Sanmartín O
Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
Reyes-Habito CM; Roh EK
J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]